Theragnostics in Neuroendocrine Tumors

Area of Science:

• Nuclear medicine
• Oncology
• Radiology

Background:

• Somatostatin receptor (SSTR)-targeted imaging plays a crucial role in the management of neuroendocrine tumors (NETs).
• It aids in diagnosis, staging, treatment selection, and response assessment.
• ⁶⁸Ga-labeled somatostatin analogs PET/CT offers high sensitivity and specificity for NET detection.

Purpose of the Study:

• To highlight the diagnostic and therapeutic utility of SSTR-targeted imaging in NETs.
• To emphasize the complementary role of metabolic imaging (¹⁸F-FDG PET/CT) with molecular imaging.
• To present the efficacy of peptide receptor radionuclide therapy (PRRT).

Main Methods:

• Utilizing PET with ⁶⁸Ga-labeled somatostatin analogs for molecular imaging.
• Employing PET with ¹⁸F-FDG/CT for metabolic assessment.
• Evaluating treatment response following PRRT.

Main Results:

• ⁶⁸Ga-SSTR PET/CT demonstrates excellent sensitivity and specificity for diagnosing and staging NETs.
• ¹⁸F-FDG PET/CT complements ⁶⁸Ga-SSTR PET/CT for personalized NET therapy.
• PRRT achieves a documented response rate of 70% to 80% in NET patients.

Conclusions:

• SSTR-targeted imaging is a cornerstone in the multimodal management of NETs.
• Combined molecular and metabolic imaging facilitates personalized therapeutic strategies.
• PRRT is an effective treatment option for NETs with a high response rate.